Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914901 | 1.00 | LDHA (0.56) | LDHAKMT2APPARGMMP1MME | |
| SCHEMBL1915678 | 0.87 | MME (0.42) | LDHAKMT2APPARGMMP1MME | |
| SCHEMBL7429464 | 0.86 | POLB (0.46) | LDHAKMT2APPARGMMP1MME | |
| SCHEMBL26754203 | 0.86 | MME (0.48) | KMT2APPARGMMEPPARACA2 | |
| SCHEMBL1915759 | 0.86 | MME (0.48) | KMT2APPARGMMEPPARACA2 | |
| SCHEMBL1704171 | 0.85 | CPA1 (0.60) | MMECA2CA9 | |
| SCHEMBL1704913 | 0.85 | CPA1 (0.60) | MMECA2CA9 | |
| SCHEMBL1915766 | 0.85 | CPA1 (0.60) | MMECA2CA9 | |
| SCHEMBL5702592 | 0.85 | LDHA (0.46) | LDHAKMT2APPARGMMP1PPARA | |
| SCHEMBL16232083 | 0.84 | MME (0.64) | MMEPOLBCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10278975-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3077401-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3077401-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015085007-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-10278975-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | LDHA 752/4885KMT2A 3648/4885PPARG 132/4885 |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | LDHA 3625/4885KMT2A 2568/4885PPARG 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.